Aducanumab Has Been Discontinued and Should Not Be Used for Alzheimer's Disease
Aducanumab received FDA accelerated approval in June 2021 but its development and sale has been discontinued, and it was never supported by CMS for payment—making it clinically obsolete. 1, 2 You should instead consider the currently available anti-amyloid monoclonal antibodies: lecanemab (which has full FDA approval as of July 2023 with CMS reimbursement) or donanemab (FDA approved in 2024). 1
Why Aducanumab Failed in Clinical Practice
Lack of Payer Support
- CMS explicitly refused to support payment for aducanumab, severely limiting access 1
- The manufacturer subsequently discontinued its development and sale 1
- This occurred despite FDA accelerated approval based on amyloid plaque reduction as a surrogate endpoint
Controversial Efficacy Data
The two pivotal Phase 3 trials (EMERGE and ENGAGE) showed discordant results 3:
- EMERGE met its primary endpoint: High-dose aducanumab showed a 0.39-point improvement on CDR-SB compared to placebo (22% reduction in decline, P=0.012)
- ENGAGE failed completely: No benefit observed (0.03-point difference, P=0.833)
- Both trials were actually halted early for futility based on pooled interim analysis, then later reanalyzed with additional data
Meta-Analysis Shows Minimal Clinical Benefit
A 2026 Cochrane systematic review of all anti-amyloid antibodies including aducanumab found 4:
- Cognitive function: Trivial effect (SMD -0.11 on ADAS-Cog)
- Dementia severity: Little to no difference (SMD -0.12 on CDR-SB)
- Functional ability: Probably little to no meaningful difference
- The review concluded that "successful removal of amyloid from the brain does not seem to be associated with clinically meaningful effects"
The Current Anti-Amyloid Landscape
Available Alternatives
If you're considering disease-modifying therapy for early Alzheimer's disease, the appropriate options are 1:
- Lecanemab (Leqembi): Full FDA approval July 2023, CMS reimbursement available when patients are registered in approved registries
- Donanemab (Kisunla): FDA approved June 2024
Patient Selection Criteria for Anti-Amyloid Therapy
These agents are indicated for early-stage AD only (MCI due to AD or mild AD dementia) with confirmed amyloid pathology 1.
Absolute contraindications include 5:
- Evidence of intracerebral hemorrhage
- More than 4 cerebral microbleeds (CMBs)
- Any cortical superficial siderosis (for lecanemab; donanemab trials permitted one focus)
- Probable cerebral amyloid angiopathy (CAA) by Boston criteria v2.0 requires careful risk-benefit assessment
Required Infrastructure
Administering anti-amyloid monoclonal antibodies demands 1:
- Biomarker confirmation of amyloid pathology (amyloid PET or CSF testing)
- Baseline brain MRI to exclude hemorrhagic lesions
- Serial MRI monitoring for amyloid-related imaging abnormalities (ARIA)
- Multidisciplinary team with specialty expertise
- Infusion capabilities (though subcutaneous formulations are in development)
Safety Profile Common to All Anti-Amyloid Antibodies
ARIA Risk
All anti-amyloid monoclonal antibodies, including aducanumab, carry significant risk of ARIA 6, 7, 4:
- ARIA-E (edema): Increased by approximately 107 per 1000 patients
- ARIA-H (hemorrhage): Variable rates across agents
- Most ARIA is asymptomatic, but symptomatic cases occur and can be catastrophic
- Pre-existing CAA substantially increases ARIA risk 5
Monitoring Requirements
For any anti-amyloid therapy 8:
- Pre-treatment MRI is mandatory to establish baseline
- Serial MRI monitoring during treatment to detect ARIA
- MRI without contrast is sufficient for ARIA detection
- Infusion reactions require anticipatory management
Clinical Bottom Line
Do not prescribe aducanumab—it is no longer available. If you are evaluating a patient with early Alzheimer's disease for disease-modifying therapy, the conversation should focus on lecanemab or donanemab, with realistic expectations about modest clinical benefits (approximately 30% slowing of decline over 18 months) 6 weighed against ARIA risks and substantial healthcare system demands. The evidence suggests that even when amyloid is successfully cleared from the brain, the clinical impact on cognition, function, and quality of life remains marginal at best 4.